Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLLISTIM vs BRAVELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Ovulation induction in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies,Spermatogenesis induction in men with hypogonadotropic hypogonadism
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
The terminal elimination half-life ranges from 16 to 24 hours (mean ~19 hours) following subcutaneous administration. In patients with renal impairment, half-life may be prolonged, necessitating dose adjustment.
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
Follitropin beta is metabolized primarily in the liver and kidneys via proteolytic degradation; no specific cytochrome P450 involvement.
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Primarily renal; approximately 70% of the dose is excreted unchanged in urine. A minor fraction (less than 5%) appears in feces via biliary elimination. The remainder is metabolized via hepatic pathways to inactive metabolites.
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Approximately 45-50% bound, primarily to albumin and to a lesser extent to alpha-2-macroglobulin.
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
Volume of distribution is approximately 0.3 L/kg (range 0.2-0.4 L/kg), consistent with distribution largely into extracellular fluid.
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
Subcutaneous: Approximately 77% (compared to intravenous administration). Intramuscular: approximately 75%. Not available for other routes.
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
No specific guidelines; use caution in severe impairment (e GFR <30 m L/min/1.73m²) due to limited data.
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C) due to limited data.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Not FDA-approved for pediatric use; off-label doses: 75-150 IU subcutaneously daily, weight-based titration (1.5-2.25 IU/kg/day) for adolescent males with hypogonadotropic hypogonadism.
Not indicated for use in pediatric patients; safety and efficacy not established.
Not indicated for geriatric use; no dose adjustment recommended, but limited data in elderly >65 years.
Not indicated for use in geriatric patients; safety and efficacy not established.
Follistim should be used only by physicians experienced in infertility treatment. It may cause ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Serious pulmonary and vascular events have been reported.
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
Ovarian hyperstimulation syndrome (OHSS) can be severe; monitor ovarian response. Risk of multiple gestation and ectopic pregnancy. Ovarian torsion and adnexal torsion reported. Thromboembolic events. Ovarian enlargement may occur. Patients with porphyria may exacerbate condition.
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
Hypersensitivity to follitropin beta or any component. High levels of FSH indicating primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Ovarian cyst or enlargement unrelated to PCOS. Pregnancy. Sex hormone-dependent tumors (e.g., ovarian, breast, uterine, pituitary). Abnormal genital bleeding of undetermined origin.
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
No specific food interactions are documented. Grapefruit and grapefruit juice may potentially affect hormone metabolism, though not established for Follistim; advise patients to maintain a consistent diet and report unusual changes.
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and use is contraindicated in pregnant women. In the first trimester, exposure may cause fetal harm; however, no well-controlled studies exist. The drug is not used after conception, as its sole indication is for ovulation induction and controlled ovarian stimulation prior to assisted reproductive technologies.
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
FOLLISTIM is not recommended for use during breastfeeding. It is not known whether follitropin beta is excreted in human milk. Given the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio is available.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
There are no recommended dosing adjustments for FOLLISTIM during pregnancy because the drug is contraindicated and not used in pregnancy. Pregnancy results from treatment, at which point FOLLISTIM is discontinued. No pharmacokinetic changes are studied in pregnancy as it is not administered to pregnant women.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
Follistim (follitropin beta) is a recombinant FSH used for ovulation induction and controlled ovarian stimulation. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing. Risk of ovarian hyperstimulation syndrome (OHSS) increases with high estradiol (>3000 pg/m L) and multiple follicles. Do not use in primary ovarian failure, uncontrolled thyroid/adrenal disorders, or sex hormone-dependent tumors. For subcutaneous administration; rotate injection sites.
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
Follistim is injected subcutaneously exactly as prescribed; do not skip or change dose without talking to your doctor.,You will need regular blood tests and ultrasounds to monitor your response and adjust treatment.,Common side effects include injection site reactions, headache, nausea, and bloating.,Contact your doctor immediately if you experience severe pelvic pain, sudden weight gain, or difficulty breathing, which could indicate ovarian hyperstimulation syndrome (OHSS).,Follistim increases the chance of multiple pregnancy (twins, triplets).,Store vials in the refrigerator, not frozen, and protect from light. Do not use if solution is cloudy or contains particles.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLLISTIM vs BRAVELLE, answered by our medical review team.
FOLLISTIM is a Gonadotropin that works by Follistim (follitropin beta) is a recombinant follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and steroidogenesis.. BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLLISTIM and BRAVELLE depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLLISTIM is: Subcutaneous: 75-300 IU once daily for 7-21 days, adjusted based on response. Intramuscular: 75-150 IU once daily for 7-21 days.. The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLLISTIM and BRAVELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLLISTIM is classified as Category C. FOLLISTIM (follitropin beta) is classified as Pregnancy Category X. There is no indication for use during pregnancy. Animal studies have shown evidence of fetal abnormalities, and . BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.